retatrutide trial Weight Loss Results:Trial Data and FDA Status Retatrutide Delivers Bariatric-Level Weight Loss

While the efficacy data for retatrutide is exceptionally promising, maintaining rigorous clinical oversight is paramount

A 28.3% reduction in body weight averaging 70.3 pounds lost over 80 weeks is the headline number from retatrutides TRIUMPH-1 phase 3 trial, and it lands at a moment when the obesity pharmacology field thought it had already seen its ceiling

Retatrutide is the first triple-agonist GLP-1/GIP/Glucagon medication in Phase 3 trials, made by Eli Lilly

Reconstituting a 10 mg vial step by step Reconstitution is where most mistakes happen

The future directions and challenges of new small-molecule GLP-1R agonists, such as danuglipron, are multifaceted

What Happens If You Stop Taking GLP-1